Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: Randomized, controlled, phase II study in Piura, Peru

Vaccine

Volumn 30, Issue 41, 2012, Pages 5935-5941

  Lanata, Claudio F ^a   Andrade, Teresa ^a   Gil, Ana I ^a   Terrones, Cynthia ^a   Valladolid, Omar ^a   Zambrano, Betzana ^b   Saville, Melanie ^c   Crevat, Denis ^c  

^a INSTITUTO DE INVESTIGACIÓN NUTRICIONAL   (Peru)

^b Sanofi Pasteur   (Uruguay)

^c SANOFI PASTEUR   (France)

Author keywords

Children; Flavivirus vaccine; Live vaccine; Phase II clinical trial; Tetravalent dengue vaccine; Yellow fever vaccine

Indexed keywords

CYD TDV; DENGUE VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; PNEUMO23; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ARTICLE; ASTHENIA; CHILD; CONTROLLED STUDY; DRUG SAFETY; ENDEMIC DISEASE; ERYTHEMA; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; MYALGIA; PAIN; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEROTYPE; SINGLE BLIND PROCEDURE; SWELLING; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CHILD; CHILD, PRESCHOOL; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; MALE; PERU; VACCINATION; YELLOW FEVER VACCINE;

EID: 84865325628     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.07.043     Document Type: Article

References (20)

1. Jentes E.S., Poumerol G., Gershman M.D., Hill D.R., Lemarchand J., Lewis R.F., et al. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the informal WHO working group on geographic risk for yellow fever. Lancet Infect Dis 2011, 11:622-632.
2. Guzman M.G., Halstead S.B., Artsob H., Buchy P., Farrar J., Gubler D.J., et al. Dengue: a continuing global threat. Nat Rev Microbiol 2010, 8:S7-S16.
3. San Martín J.L., Brathwaite O., Zambrano B., Solórzano J.O., Bouckenooghe A., Dayan G.H., et al. The epidemiology of dengue in the Americas over the last three decades: a worrisome reality. Am J Trop Med Hyg 2010, 82:128-135.
4. Monath T.P., Cetron M.S., Teuwen D.E. Yellow fever vaccine. Vaccines 2008, 959-1055. Saunders Elsevier, Maryland Heights. 5th ed. S. Plotkin, W. Orenstein, P. Offit (Eds.).
5. Murrell S., Wu S.C., Butler M. Review of dengue virus and the development of a vaccine. Biotechnol Adv 2011, 29:239-247.
6. Schmitz J., Roehrig J., Barrett A., Hombach J. Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine 2011, 29:7276-7284.
7. Guy B., Barrere B., Malinowski C., Saville M., Teyssou R., Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011, 29:7229-7241.
8. Guirakhoo F., Weltzin R., Chambers T.J., Zhang Z.X., Soike K., Ratterree M., et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 2000, 74:5477-5485.
9. Morrison D., Legg T.J., Reed L.D., Billings C.W., Forrat R., Yoksan S., et al. A novel tetravalent dengue vaccine is well-tolerated and immunogenic against all four serotypes in flavivirus-naïve adults. J Infect Dis 2010, 201:370-377.
10. Capeding R.Z., Luna I.A., Bomasang E., Lupisana S., Lang J., Forrat R., et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 2011, 29:3863-3872.
11. Poo J.L., Galán Herrera J.F., Forrat R., Zambrano B., Lang J., Dayan G. Live-attenuated tetravalent dengue vaccine in dengue-naïve children, adolescents and adults in Mexico city: randomized controlled phase 1 trial of safety and immunogenicity. Ped Infect Dis J 2011, 30:e9-e17.
12. Scott R.M., Eckels K.H., Bancroft W.H., Summers P.L., McCown J.M., Anderson J.H., et al. Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status. J Infect Dis 1983, 135:4201-4203.
13. Guirakhoo F., Kitchener S., Morrison D., Forrat R., McCarthy K., Nichols R., et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2006, 2:60-67.
14. World Health Organization Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated) 2011, WHO, Geneva, (WHO/BS/11.2159) http://www.who.int/biologicals/BS2159_Dengue_WITH_LINE_NUMBERS_TRS_v47_18Jul2011_sub2.pdf [accessed 22.03.12].
15. World Health Organization Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses 2007, WHO, Geneva, (WHO/IVB/07.07) http://whqlibdoc.who.int/hq/2007/who_ivb_07.07_eng.pdf [accessed 29.07.12].
16. Mantel N., Aguirre M., Gulia S., Girerd-Chambaz Y., Colombani S., Moste C., et al. Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines. J Virol Methods 2008, 151:40-46.
17. Forshey B.M., Morrison A.C., Cruz C., Rocha C., Vilcarromero S., Guevara C., et al. Dengue virus serotype 4, Northeastern Peru, 2008. Emerg Infect Dis 2009, 15:1815. (Erratum in: Emerg Infect Dis 2010;16:177).
18. Qiao M., Shaw D., Forrat R., Wartel-Tram A., Lang J. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity and safety of a tetravalent dengue vaccine in humans. Am J Trop Med Hyg 2011, 85:724-731.
19. Balmaseda A., Standish K., Mercado J.C., Matute J.C., Tellez Y., Saborio S., et al. Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua. J Infect Dis 2010, 201:5-14.
20. Guy B., Guirakhoo F., Barban V., Higgs S., Monath T.P., Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010, 28:632-649.